ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.876,11
0,94%
Brent Oil
84,85
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) Notícias

GTHX

G1 Therapeutics (GTHX)

G1 Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GTHX
DataHoraFonteTítuloCódigoCompanhia
24/06/202407:30GlobeNewswire Inc.G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)NASDAQ:GTHXG1 Therapeutics Inc
14/06/202417:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
14/06/202417:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
05/06/202408:00GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
28/05/202407:30GlobeNewswire Inc.Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)NASDAQ:GTHXG1 Therapeutics Inc
23/05/202418:06GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingNASDAQ:GTHXG1 Therapeutics Inc
22/05/202411:00GlobeNewswire Inc.G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitNASDAQ:GTHXG1 Therapeutics Inc
22/05/202407:30GlobeNewswire Inc.G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesNASDAQ:GTHXG1 Therapeutics Inc
01/05/202407:30GlobeNewswire Inc.G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
01/05/202407:25GlobeNewswire Inc.G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibNASDAQ:GTHXG1 Therapeutics Inc
17/04/202410:00GlobeNewswire Inc.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024NASDAQ:GTHXG1 Therapeutics Inc
04/04/202411:30GlobeNewswire Inc.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
28/02/202408:30GlobeNewswire Inc.G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/02/202410:30GlobeNewswire Inc.G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:GTHXG1 Therapeutics Inc
15/02/202410:30GlobeNewswire Inc.G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024NASDAQ:GTHXG1 Therapeutics Inc
12/02/202418:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GTHXG1 Therapeutics Inc
12/02/202418:05GlobeNewswire Inc.G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeNASDAQ:GTHXG1 Therapeutics Inc
08/01/202408:45GlobeNewswire Inc.G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
03/01/202411:00GlobeNewswire Inc.G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
05/12/202311:26GlobeNewswire Inc.G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer TherapyNASDAQ:GTHXG1 Therapeutics Inc
29/11/202322:37GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumNASDAQ:GTHXG1 Therapeutics Inc
01/11/202317:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GTHXG1 Therapeutics Inc
01/11/202317:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GTHXG1 Therapeutics Inc
01/11/202307:30GlobeNewswire Inc.G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/10/202308:00GlobeNewswire Inc.Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202309:00GlobeNewswire Inc.G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202308:30GlobeNewswire Inc.G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023NASDAQ:GTHXG1 Therapeutics Inc
16/10/202310:00GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care SymposiumNASDAQ:GTHXG1 Therapeutics Inc
18/09/202308:00GlobeNewswire Inc.Black Diamond Therapeutics Announces CEO TransitionNASDAQ:GTHXG1 Therapeutics Inc
05/09/202312:00GlobeNewswire Inc.G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:GTHXG1 Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GTHX

Seu Histórico Recente

AMEX
BDCX
ETRACS Qutly Pay 1.5x Le...
BIT
F17480
Vontobel Financial Produ...
BIT
I09825
IT0005574519 20240902 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados